Peer-reviewed article
Progesterone Exposure in Pregnancy, Obstetric Stabilization, and Developmental Outcomes: A Focused Review of Direct and Indirect Pathways.
Dugalic S, Dugalic MG, Milincic M, Ivanovic K ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This is a medical literature review about progesterone hormone use during pregnancy and its potential effects on fetal and child development. It examines both direct molecular pathways and indirect effects through obstetric stabilization, distinguishing between natural progesterone and synthetic alternatives. The review concludes that natural progesterone appears acceptable for recognized clinical indications based on available data, but long-term evidence in children remains limited. The analysis emphasizes that different formulations and uses should be evaluated separately rather than as interchangeable treatments.
Key points
- Direct progesterone pathways (receptor signaling, neuroactive metabolites, epigenetics) lack persistent human evidence for therapy-induced molecular programming
- Indirect pathways are better supported, including placental stabilization, cervical integrity, and prevention of prematurity in selected pregnancies
- Synthetic progestogens and 17-alpha hydroxyprogesterone caproate require separate evaluation due to regulatory concerns about efficacy and possible offspring safety signals
- Natural progesterone shows no consistent early adverse signals for recognized indications, but long-term offspring data remain limited
- Evidence cannot be generalized across different formulations or types of progestins
Limitations
This is a narrative review synthesizing heterogeneous literature rather than original research with child outcome data. The available evidence has significant methodological variation across studies (different indications, formulations, doses, timing, and follow-up periods), limiting generalizability, and long-term child developmental outcomes beyond early childhood are not adequately documented.
Abstract
Background Progesterone is an endogenous pregnancy hormone widely used in reproductive medicine and obstetrics. Its developmental relevance should be interpreted by distinguishing direct molecular plausibility from indirect obstetric effects, including stabilization of the maternal-decidual-placental maternal-decidual-placental environment, cervical stability, and prolongation of gestation. Methods A focused qualitative narrative review was performed using targeted literature searches and thematic synthesis. This approach was chosen because the available evidence is heterogeneous with respect to indication, formulation, route, dose, timing, comparator group, and offspring follow-up, making quantitative synthesis inappropriate for the present objective. Results Direct progesterone-related pathways include receptor-mediated signaling, neuroactive metabolites, and biologically plausible epigenetic regulation; however, human evidence for persistent therapy-induced molecular programming remains limited. Indirect pathways are better supported and include decidualization, immune tolerance, placental stabilization, cervical integrity, uterine quiescence, and prevention of prematurity in selected pregnancies. Clinical evidence should be interpreted separately for placebo-controlled trials, untreated pathological cohorts, and observational follow-up studies because underlying maternal conditions may themselves influence offspring outcomes. Potential risk signals also require formulation-specific interpretation, particularly for synthetic progestogens and 17-alpha hydroxyprogesterone caproate, for which long-term observational data and regulatory reassessments have raised concerns regarding efficacy and possible offspring safety signals. Inadvertent exposure to contraceptive progestins during unrecognized pregnancy, including progestin-only preparations and levonorgestrel-releasing intrauterine systems, should be considered separately from therapeutic obstetric progesterone use. Available evidence has not shown a consistent early adverse signal for natural progesterone when used for recognized indications, although long-term offspring data remain limited and cannot be generalized to synthetic progestogens or 17-alpha hydroxyprogesterone caproate. Conclusions Progesterone-related therapies should be considered indication-specific and formulation-specific rather than interchangeable. Current evidence supports a cautious and comparator-aware interpretation: natural progesterone appears acceptable for recognized clinical indications based on available short-term and early childhood data, but evidence beyond early childhood remains insufficient for broad safety generalizations.